Julia R. Brinton

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Cooley advised IAA, Inc. (IAA), a global digital marketplace connecting vehicle buyers and sellers, on its cross-border stock and cash acquisition by Ritchie Bros., which closed on Monday, March 20.

Cooley advised Insurance Auto Auctions (IAA), a global digital marketplace connecting vehicle buyers and sellers, on an amendment to its previously announced merger agreement with Ritchie Bros., which provides for the stock and cash acquisition of IAA by Ritchie Bros.

Cooley advised Oyster Point Pharma, a top ophthalmology-focused biopharmaceutical company, on its definitive agreement to be acquired by global healthcare company Viatris. Partners Mika Reiner Mayer, Brandon Fenn, Div Gupta and Ian Nussbaum led the Cooley team advising Oyster Point Pharma.

Cooley advised Insurance Auto Auctions (IAA), a global digital marketplace connecting vehicle buyers and sellers, on its definitive merger agreement, under which Ritchie Bros. will acquire IAA in a cross-border stock and cash transaction valued at approximately $7.3 billion.